Your browser doesn't support javascript.
loading
Genomic evolution shapes prostate cancer disease type.
Woodcock, Dan J; Sahli, Atef; Teslo, Ruxandra; Bhandari, Vinayak; Gruber, Andreas J; Ziubroniewicz, Aleksandra; Gundem, Gunes; Xu, Yaobo; Butler, Adam; Anokian, Ezequiel; Pope, Bernard J; Jung, Chol-Hee; Tarabichi, Maxime; Dentro, Stefan C; Farmery, J Henry R; Van Loo, Peter; Warren, Anne Y; Gnanapragasam, Vincent; Hamdy, Freddie C; Bova, G Steven; Foster, Christopher S; Neal, David E; Lu, Yong-Jie; Kote-Jarai, Zsofia; Fraser, Michael; Bristow, Robert G; Boutros, Paul C; Costello, Anthony J; Corcoran, Niall M; Hovens, Christopher M; Massie, Charlie E; Lynch, Andy G; Brewer, Daniel S; Eeles, Rosalind A; Cooper, Colin S; Wedge, David C.
Affiliation
  • Woodcock DJ; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
  • Sahli A; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
  • Teslo R; Big Data Institute, University of Oxford, Oxford, UK.
  • Bhandari V; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Gruber AJ; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Department of Biology, University of Konstanz, Konstanz, Germany.
  • Ziubroniewicz A; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
  • Gundem G; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Xu Y; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Butler A; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Anokian E; The Institute of Cancer Research, London, UK.
  • Pope BJ; Melbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia; Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia; Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Jung CH; Melbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia.
  • Tarabichi M; The Francis Crick Institute, London, UK; Institute of Interdisciplinary Research (IRIBHM), Universite Libre de Bruxelles, Brussels, Belgium.
  • Dentro SC; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; The Francis Crick Institute, London, UK.
  • Farmery JHR; Statistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Van Loo P; The Francis Crick Institute, London, UK; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Warren AY; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Gnanapragasam V; Cambridge Urology Translational Research and Clinical Trials Office, Addenbrooke's Hospital, Cambridge, UK; Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Hamdy FC; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Bova GS; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
  • Foster CS; HCA Laboratories, London, UK.
  • Neal DE; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Lu YJ; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Kote-Jarai Z; The Institute of Cancer Research, London, UK.
  • Fraser M; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Bristow RG; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; CRUK Manchester Institute, University of Manchester, Manche
  • Boutros PC; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Departments of Human Genetics and Urology, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
  • Costello AJ; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • Corcoran NM; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • Hovens CM; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • Massie CE; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Early Detection Programme and Urological Malignancies Programme, Cancer Research UK Cambridge Centre, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Lynch AG; Statistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK; School of Medicine/School of Mathematics and Statistics, University of St Andrews, St Andrews, UK.
  • Brewer DS; Norwich Medical School, University of East Anglia, Norwich, UK; Earlham Institute, Norwich, UK. Electronic address: d.brewer@uea.ac.uk.
  • Eeles RA; The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: ros.eeles@icr.ac.uk.
  • Cooper CS; The Institute of Cancer Research, London, UK; Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: colin.cooper@uea.ac.uk.
  • Wedge DC; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK; Manchester NIHR Biomedical Research Centre, Manche
Cell Genom ; 4(3): 100511, 2024 Mar 13.
Article in En | MEDLINE | ID: mdl-38428419
ABSTRACT
The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Limits: Humans / Male Language: En Journal: Cell Genom Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Limits: Humans / Male Language: En Journal: Cell Genom Year: 2024 Document type: Article